Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

NCT06784791 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer (NSCLC)

Interventions

DRUG: Amivantamab Intravenous
DRUG: Carboplatin/Pemetrexed

Sponsor

University Hospital, Essen